A detailed history of Advisor Group Holdings, Inc. transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 16,734 shares of ATRA stock, worth $129,019. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,734
Previous 2,234 649.06%
Holding current value
$129,019
Previous $1,000 1000.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$0.44 - $1.22 $6,380 - $17,690
14,500 Added 649.06%
16,734 $11,000
Q4 2023

Feb 12, 2024

SELL
$0.23 - $1.74 $503 - $3,810
-2,190 Reduced 49.5%
2,234 $1,000
Q3 2023

Nov 13, 2023

BUY
$1.41 - $2.31 $153 - $251
109 Added 2.53%
4,424 $6,000
Q2 2023

Aug 10, 2023

SELL
$1.5 - $3.04 $411 - $832
-274 Reduced 5.97%
4,315 $6,000
Q1 2023

May 12, 2023

SELL
$2.8 - $5.46 $184 - $360
-66 Reduced 1.42%
4,589 $13,000
Q4 2022

Feb 10, 2023

BUY
$2.85 - $5.18 $10,841 - $19,704
3,804 Added 447.0%
4,655 $15,000
Q3 2022

Nov 14, 2022

SELL
$2.85 - $8.73 $48 - $148
-17 Reduced 1.96%
851 $3,000
Q2 2022

Aug 10, 2022

BUY
$4.69 - $9.84 $529 - $1,111
113 Added 14.97%
868 $7,000
Q1 2022

May 04, 2022

BUY
$8.44 - $16.89 $953 - $1,908
113 Added 17.6%
755 $7,000
Q3 2021

Nov 05, 2021

SELL
$11.99 - $17.9 $7,781 - $11,617
-649 Reduced 50.27%
642 $11,000
Q2 2021

Aug 02, 2021

SELL
$12.89 - $16.58 $953 - $1,226
-74 Reduced 5.42%
1,291 $21,000
Q1 2021

May 13, 2021

SELL
$14.0 - $20.72 $410,732 - $607,883
-29,338 Reduced 95.55%
1,365 $19,000
Q4 2020

Feb 10, 2021

BUY
$12.67 - $26.23 $58,446 - $120,998
4,613 Added 17.68%
30,703 $602,000
Q3 2020

Nov 12, 2020

BUY
$11.92 - $15.87 $306,940 - $408,652
25,750 Added 7573.53%
26,090 $338,000
Q2 2020

Aug 14, 2020

SELL
$7.53 - $14.93 $4,367 - $8,659
-580 Reduced 63.04%
340 $4,000
Q1 2020

May 18, 2020

BUY
$5.69 - $17.78 $5,234 - $16,357
920 New
920 $8,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.